Second-line treatment of HER2+ metastatic breast cancer (MBC): Trastuzumab (T) beyond progression or lapatinib (L)? A retrospective database study.
Rinat Yerushalmi
Honoraria - GlaxoSmithKline; Roche
Ilan Feldhamer
No relevant relationships to disclose
Sari Greenberg-Dotan
No relevant relationships to disclose
Haim Bitterman
No relevant relationships to disclose
Ariel Hammerman
No relevant relationships to disclose